Maverick Medical AI Completes Real-Time Autonomous Medical Coding Implementation at RadNet

Maverick Medical AI has announced the successful deployment of its real-time, AI-powered autonomous medical coding solution at all 399 RadNet, Inc. (NASDAQ: RDNT) locations. RadNet is a national leader in delivering high-quality, cost-effective outpatient diagnostic imaging services. RadNet has successfully…

Read MoreMaverick Medical AI Completes Real-Time Autonomous Medical Coding Implementation at RadNet

Life Healthcare Reports Strong H2-2024 Performance and Robust International Sales

Life Healthcare delivered a strong performance in the second half of 2024, particularly in its acute and complementary healthcare businesses in southern Africa. Acute hospital patient volumes showed positive growth, with paid patient days (PPDs) increasing by 1.6%. Occupancy rates…

Read MoreLife Healthcare Reports Strong H2-2024 Performance and Robust International Sales

FDA Approves AOP Health’s Rapiblyk™ (Landiolol) for Atrial Fibrillation and Flutter in Critical Care

AOP Orphan Pharmaceuticals GmbH (AOP Health), based in Vienna, Austria, has announced that the U.S. Food and Drug Administration (FDA) has approved Rapiblyk™ (landiolol) for the treatment of supraventricular tachycardia (SVT), including atrial fibrillation and atrial flutter, in critical care…

Read MoreFDA Approves AOP Health’s Rapiblyk™ (Landiolol) for Atrial Fibrillation and Flutter in Critical Care

Galderma’s Phase III OLYMPIA 1 Data Shows Nemolizumab Improves Prurigo Nodularis Symptoms

Galderma recently announced that the full results from the Phase III OLYMPIA 1 trial, which evaluated the efficacy and safety of nemolizumab in adults with moderate-to-severe prurigo nodularis, were published in JAMA Dermatology. The data from this trial, in conjunction…

Read MoreGalderma’s Phase III OLYMPIA 1 Data Shows Nemolizumab Improves Prurigo Nodularis Symptoms

QIAGEN Expands QIAstat-Dx with New Barcelona Site to Boost Infectious Disease and Precision Medicine Growth

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today revealed plans to relocate its QIAstat-Dx operations to a new facility in Esplugues de Llobregat, near Barcelona. This move is part of a multi-year investment aimed at expanding and strengthening the company’s…

Read MoreQIAGEN Expands QIAstat-Dx with New Barcelona Site to Boost Infectious Disease and Precision Medicine Growth